Estimated longevity benefit: +3.3 years. Evidence score: 61/100.
The combination of the mTOR inhibitor rapamycin and the glucose-modulator acarbose produced the largest lifespan extension ever recorded in the NIA Interventions Testing Program: +37% in males, +28% in females — outperforming either drug alone and providing the first strong animal evidence that combination longevity protocols beat single agents.